Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome: Report of a prospective uncontrolled multicenter study

Pediatric Nephrology

Volumn 13, Issue 1, 1999, Pages 7-12

  Querfeld, U ^a   Kohl, B ^b   Fiehn, W ^b   Minor, T ^c   Michalk, D ^a   Scharer K ^d   Muller Wiefel D E ^e  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antioxidants; Hyperlipidemia; Nephrotic syndrome; Probucol

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PROBUCOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; ELECTROCARDIOGRAM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIPID PEROXIDATION; MULTICENTER STUDY; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; QT INTERVAL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERLIPIDEMIAS; NEPHROTIC SYNDROME; PROBUCOL; PROSPECTIVE STUDIES;

EID: 0032966646     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050554     Document Type: Article

References (46)

1. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman B (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642
2. Curry RC, Roberts WC (1977) Status of the coronary arteries in the nephrotic syndrome. Am J Med 63:183-192
3. Moorhead JF, El-Nahas M, Chan MK, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet II:1309-1312
4. Diamond J (1989) Hyperlipidemia of nephrosis: pathophysiologic role in progressive glomerular disease. Am J Med 87:25N-29N
5. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP (1991) Hyperlipidemia and progressive renal disease. Kidney Int 39:S41-S48
6. Querfeld U (1993) Disturbances of lipid metabolism in children with chronic renal failure. Pediatr Nephrol 7:749-757
7. Kleinveld HA, Demacker PN, Stalenhoef AF (1994) Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 14:1386-1391
8. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641-644
9. Steinberg D, Parthasarathy S, Carew TE (1988) In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 62:6B-12B
10. Franceschini G, Werba JP, Calabresi L (1994) Drug control of reverse cholesterol transport. Pharmacol Ther 61:289-324
11. Goldberg RB, Mendez A (1988) Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Am J Cardiol 62:57B-59B
12. Kaneko M, Hayashi J, Saito I, Miyasaka N (1996) Probucol downregulates E-selection expression on cultured human vascular endothelial cells. Arterioscler Thromb Vasc Biol 16:1047-1051
13. Baumann DS, Doblas M, Schonfeld G, Sicard GA, Daugherty A (1994) Probucol reduces the cellularity of aortic intimal thickening at anastomotic regions adjacent to prosthetic grafts in cholesterol-fed rabbits. Arterioscler Thromb 14:162-167
14. Ferns GAA, Forster L, Stewart-Lee A, Nourooz-Zadeh J, Anggard EE (1993) Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 100:171-181
15. Fujita M, Shirai K (1996) A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 23:598-602
16. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-493
17. Regnstrom J, Walldius G, Nilsson S, Elinder LS, Johansson J, Molgaard J, Holme I, Olsson AG, Nilsson J (1996) The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 125:217-229
18. Naito H, Hirano T (1994) Probucol suppresses the development of chronic renal failure in Dahl salt-sensitive rats: an animal model of spontaneous focal and segmental glomerulosclerosis (letter). Nephron 67:125-126
19. Hattori M, Ito K, Kawaguchi H, Yamaguchi Y (1994) Probucol reduces renal injury in the ExHC rat. Nephron 67:459-468
20. Modi KS, Schreiner GF, Purkerson ML, Klahr S (1992) Effects of probucol on renal function and structure in rats with subtotal kidney ablation. J Lab Clin Med 120:310-317
21. Magil A (1996) Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. J Am Soc Nephrol 7:2340-2347
22. Hirano T, Mamo JCL, Nagano S, Sugisaki T (1991) The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. Nephron 58:95-100
23. Amenomori M, Haneda M, Morikawa J, Nishigaki I, Maeda S, Hidaka H, Kikkawa R, Shigeta Y (1994) A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron 67:109-113
24. Kohlmeier M (1986) Simplified lipoprotein analysis by means of ultracentrifugation (in German). Ärztl Lab 32:46-52 (abstract in English)
25. Wong SHY, Knight JA, Hopfer SM, Zaharia O, Leach CN, Sunderman FW (1987) Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehydethiobarbituric acid adduct. Clin Chem 33:214-220
26. Ehrich JHH, Burchert W, Schirg E, Krull F, Offner G, Hoyer PF, Brodehl J (1995) Steroid resistant nephrotic syndrome associated with spondyloepiphyseal dysplasia, transient ischemic attacks and lymphopenia. Clin Nephrol 43:89-95
27. Wanner C, Bohler J, Eckhardt HG, Wieland H, Schollmeyer P (1994) Effects of simvastatin on lipoprotein(a) and lipoprotein composition in patients with nephrotic syndrome. Clin Nephrol 41:138-143
28. Olbricht CJ, Koch KM (1992) Treatment of hyperlipidemia in nephrotic syndrome: time for a change? Nephron 62:125-129
29. Hopp L, Gilboa N, Kurland G, Weichler N, Ochard TJ (1994) Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. Pediatr Nephrol 8:290-294
30. Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S (1987) Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. Nephron 47:280-283
31. Valeri A, Gelfand J, Blum C, Appel GB (1986) Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 8:388-396
32. Wheeler DC, Ghana RS (1993) Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab 19:149-164
33. Querfeld U (1998) Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol (1999) 13: 77-84
34. Durrington PN, Miller JP (1985) Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolemia. Atherosclerosis 55:187-194
35. Heel RC, Brogden RN, Speicht TM, Avery GS (1978) Probucol - a review of its pharmacological properties and therapeutic use in patients with hypercholesterolemia. Drug 15:409-428
36. Feher MD, Webb JC, Patel DD, Lant AF, Mayne PD, Knight BL, Soutar AK (1993) Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. Atherosclerosis 103:171-180
37. O'Keefe JHJ, Stone GW, McCallister BDJ (1996) Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 77:649-652
38. Shinomiya M, Shirai K, Saito Y, Yoshida S (1993) Positive correlation between probucol in low density lipoprotein and LDL-lowering. Eur J Clin Pharmacol 45:343-346
39. Franceschini G, Chiesa G, Sirtori CR (1991) Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur J Clin Invest 21:384-388
40. Nestel PJ, Reardon MF, Fidge NH (1984) Homozygous familial hypercholesterolemia occurring with apoprotein E3 deficiency. Arteriosclerosis 4:124-129
41. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M (1993) Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 45:47-52
42. Garson A Jr, Dick M II, Fournier A, Gillette PC, Hamilton R, Kugler JD, Van Hare GF III, Vetter V, Vick GW III (1993) The long QT syndrome in children. An international study of 287 patients. Circulation 87:1866-1872
43. Finckh B, Niendorf A, Rath M, Beisiegel U (1991) Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect? Eur J Clin Pharmacol 40 [Suppl 1]:S77-S80
44. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP (1993) Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 43:1243-1250
45. Fruebis J, Steinberg D, Dresel HA, Carew TE (1994) A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 94:392-398
46. Sheetz MJ, Barnhart RL, Jackson RL, Robinson KM (1994) MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein. Metabolism 43:233-240